AI Report to Guide Care for Uncertain Lung Nodules Seen on CT Scans
Tests an AI scan report to guide care for people with lung nodules.
Plain-language title generated from the registry record
Registry title: Longitudinal AI-Assisted Management of Indeterminate Pulmonary Nodules
Key facts
- Where
- Wuhan, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a lung nodule of 6 to 30 mm that doctors cannot yet classify, and who have two earlier CT scans. It tests whether an AI report on the scans changes the management of the nodule.
- Age
- 35 years or older
- Sex
- All sexes can join.
- Disease stage
- At least one lasting lung nodule of 6 to 30 mm on the latest CT. Solid, part-solid and pure ground-glass nodules can join. The decision between watching and further tests is still open.
- Earlier treatment
- The nodule must not have been treated or finally diagnosed before. No cancer treatment in the past five years, apart from treated nonmelanoma skin cancer or in situ cervical cancer.
Main reasons for not taking part
- Active cancer or cancer treatment within the past five years (some skin and cervical cancers excepted)
- Clear metastatic disease or suspicious lymph nodes needing urgent work-up
- Important immune weakness or active lung infection needing a separate diagnostic pathway
- Taking part in an organized lung-cancer screening program with a fixed pathway
- Known pregnancy
Read by machine on 9 November 2026.
Where in China
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Trial code
- NCT07895277
- Record updated
- 26 October 2026
- Original description
Patients with indeterminate lung nodules often face a choice between continued CT surveillance and invasive investigation. This trial compares management with or without access to an AI report that matches nodules across real serial CT scans, measures change, and estimates validated malignancy or invasiveness risks. The principal question is whether offering the report reduces lung resections that yield benign pathology over 24 months. Diagnostic delay, cancer stage, treatment opportunity, complications, and longer-term cancer outcomes are also assessed.Read full original descriptionShow less
Study of Imaging Evolution of Pulmonary Nodules and Artificial Intelligence-Assisted Diagnostic and Management Strategies
Patients with indeterminate lung nodules often face a choice between continued CT surveillance and invasive investigation. This trial compares management with or without access to an AI report that matches nodules across real serial CT scans, measures change, and estimates validated malignancy or invasiveness risks. The principal question is whether offering the report reduces lung resections that yield benign pathology over 24 months. Diagnostic delay, cancer stage, treatment opportunity, complications, and longer-term cancer outcomes are also assessed.
Inclusion: 1. At least one persistent indeterminate pulmonary nodule measuring 6 to 30 mm on the latest clinically obtained CT; solid, part-solid, and pure ground-glass nodules are eligible. 2. Two CT examinations in total are already available: the latest within 30 days before randomization and an earlier examination 3 to 24 months before it. Both meet the frozen image-quality requirements for longitudinal comparison. 3. The current decision between continued surveillance and further investigation remains unresolved, with no mandatory urgent procedure or committed definitive treatment before randomization; The patient is potentially eligible for curative treatment if cancer is diagnosed, with an estimated life expectancy of at least five years independent of the study nodule. 5. Written informed consent and willingness to permit record retrieval and five-year contact.
Exclusion: 1.Definitive diagnosis or previous treatment of the target nodule; overt metastatic disease, suspicious adenopathy requiring urgent work-up, or another indication making delayed evaluation inappropriate. 2.Active malignancy or cancer treatment within the preceding five years, except definitively treated nonmelanoma skin cancer or in situ cervical cancer; Clinically important immunocompromise or active pulmonary infection requiring a separate diagnostic pathway. 4. Current participation in an organized lung-cancer screening program with a mandated management pathway incompatible with this trial. 5. CT quality or acquisition differences prevent valid longitudinal evaluation; a clearly benign lesion does not require a diagnostic management decision. 6. Known pregnancy; a conflicting interventional trial; prior randomization in this study; or consent cannot be obtained.